London Co. of Virginia Sells 12,726 Shares of Certara, Inc. (NASDAQ:CERT)

London Co. of Virginia cut its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,422,539 shares of the company’s stock after selling 12,726 shares during the period. London Co. of Virginia owned 0.88% of Certara worth $15,150,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Kopion Asset Management LLC raised its stake in Certara by 46.0% during the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after buying an additional 175,005 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Certara by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock valued at $5,660,000 after acquiring an additional 15,739 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in Certara in the fourth quarter worth approximately $1,295,000. Barclays PLC grew its holdings in shares of Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after acquiring an additional 46,880 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Certara during the 4th quarter valued at about $3,628,000. 73.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CERT has been the subject of several analyst reports. Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. JMP Securities reissued a “market perform” rating on shares of Certara in a report on Tuesday, May 6th. William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Robert W. Baird lifted their target price on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, April 11th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

Certara Price Performance

Shares of CERT stock opened at $12.13 on Tuesday. The company has a market cap of $1.97 billion, a P/E ratio of -60.65, a PEG ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock’s 50-day moving average is $11.68 and its 200 day moving average is $11.70. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $17.76.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. During the same quarter in the prior year, the business posted $0.10 EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. Research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.